Last reviewed · How we verify
Circadin
At a glance
| Generic name | Circadin |
|---|---|
| Also known as | ATC code: N05CH01, slow-release melatonin, Prolonged-release melatonin (2mg) |
| Sponsor | Neurim Pharmaceuticals Ltd. |
| Target | Cytochrome P450 1B1, Myeloperoxidase, Nuclear receptor ROR-alpha |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Disorders of initiating and maintaining sleep
Common side effects
Key clinical trials
- Effect of 1% Melatonin Gel Versus Calcium Hydroxide as an Intracanal Medicament on the Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp. (NA)
- A Study of Melatonin Concentration During Lactation
- Melatonin for Treatment of Delirium in Critically Ill Adult Patients (PHASE2)
- PICU-related Sleep and Circadian Dysregulation Pilot Study (NA)
- Studying Melatonin and Recovery in Teens (NA)
- Effect of Esketamine on Postoperative Sleep in Postmenopausal Women (NA)
- The Effect of Dexmedetomidine Infusion Alone Versus the Combination of Dexmedetomidine and Melatonin on Reduction of Post-operative Delirium (POD) After Open Brain Surgeries (PHASE4)
- Melatonin Versus Placebo for Bipolar Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Circadin CI brief — competitive landscape report
- Circadin updates RSS · CI watch RSS
- Neurim Pharmaceuticals Ltd. portfolio CI